Li D, Darden C, Osman N, Sayeed S, Jackson L, Garbinsky D, Chauhan A. Real-world clinical and patient-reported outcomes from the longitudinal telotristat ethyl treatment registry of patients with neuroendocrine tumors. Cancer Manag Res. 2022 Oct 17;14:3009-20. doi: 10.2147/CMAR.S386419
Hofheinz RD, Bruix J, Demetri GD, Grothey A, Marian M, Bartsch J, Odom D. Effect of regorafenib in delaying definitive deterioration in health-related quality of life in patients with advanced cancer of three different tumor types. Cancer Manag Res. 2021 Jul 12;13:5523-33. doi: 10.2147/CMAR.S305939
Appukkuttan S, Farej R, Miles L, Purser M, Wen L. Budget impact analysis of darolutamide for treatment of nonmetastatic castration-resistant prostate cancer. J Manag Care Spec Pharm. 2021 Feb;27(2):166-74. doi: 10.18553/jmcp.2020.20330
Graham J, Earnshaw S, Burslem K, Lim J. Budget impact analysis of afatinib for first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 substitution mutations in a U.S. health plan. J Manag Care Spec Pharm. 2018 Jun;24(6):544-53. doi: 10.18553/jmcp.2018.24.6.544
Gnanasakthy A, Hochhaus A, Giles FJ, Radich JP, Brandt P, Saglio G. ENESTfreedom trial of treatment-free remission: patient-reported quality of life before and after stopping treatment in patients with chronic myeloid leukemia in chronic phase. Poster presented at the 2017 AMCP Managed Care & Specialty Pharmacy Annual Meeting; March 27, 2017. Denver, CO. [abstract] J Manag Care Spec Pharm. 2017 Mar; 23(3a):S4.
Gnanasakthy A, Brandt P, Hughes TP. ENESTop trial of treatment-free remission: patient-reported quality of life before and after stopping treatment in patients with chronic myeloid leukemia in chronic phase. Poster presented at the 2017 AMCP Managed Care & Specialty Pharmacy Annual Meeting; March 27, 2017. Denver, CO. [abstract] J Manag Care Spec Pharm. 2017 Mar; 23(3a):S3.
Brogan AP, DeMuro C, Barrett AM, D’Alessio D, Bal V, Hogue SL. Payer perspectives on patient-reported outcomes in health care decision making: oncology examples. J Manag Care Spec Pharm. 2017 Feb;23(2):124-34. doi: 10.18553/jmcp.2017.23.2.125.
Parikh RC, Du XL, Robert MO, Lairson DR. Cost-effectiveness of treatment sequences of chemotherapies and targeted biologics for elderly metastatic colorectal cancer patients. J Manag Care Spec Pharm. 2017 Jan;23(1):64-73. doi: 10.18553/jmcp.2017.23.1.64
Cuyún Carter G, Barrett AM, Kaye JA, Liepa AM, Winfree KB, John WJ. A comprehensive review of nongenetic prognostic and predictive factors influencing the heterogeneity of outcomes in advanced non-small-cell lung cancer. Cancer Manag Res. 2014 Oct 23;2014(6):437-49. doi: 10.2147/CMAR.S63603